All In Biotech

Drug Trial Radar · NCT00037752

Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates

Use of Sibutramine in Smoking Cessation

Last checked: Nov 20, 2026Latest source record: May 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

436

Actual

Start

Sep 2002

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
University of TennesseeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
May 21, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.

Conditions

  • Cardiovascular Diseases
  • Heart Diseases
  • Obesity

Interventions

  • SibutramineDrug

    At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.

  • Behavioral Smoking Cessation ProgramBehavioral

    Both groups of participants will take part in a behavioral smoking cessation program.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-cessation weight changeTime frame: Measured at 1 year follow-up
  2. Smoking cessationTime frame: Measured at 1 year follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Tennessee Health Science Center

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.